Drug development for neurodevelopmental disorders: lessons learned from fragile X syndrome

[1]  M. Bear,et al.  Reversal of Disease-Related Pathologies in the Fragile X Mouse Model by Selective Activation of GABAB Receptors with Arbaclofen , 2012, Science Translational Medicine.

[2]  M. Bear,et al.  Hypersensitivity to mGluR5 and ERK1/2 Leads to Excessive Protein Synthesis in the Hippocampus of a Mouse Model of Fragile X Syndrome , 2010, The Journal of Neuroscience.

[3]  S. Kushner,et al.  Fragile X mice have robust mGluR5-dependent alterations of social behaviour in the Automated Tube Test , 2015, Neurobiology of Disease.

[4]  D. Licatalosi,et al.  FMRP Stalls Ribosomal Translocation on mRNAs Linked to Synaptic Function and Autism , 2011, Cell.

[5]  S. Warren,et al.  The fragile X mental retardation protein inhibits translation via interacting with mRNA. , 2001, Nucleic acids research.

[6]  J. Olson,et al.  Hedgehog pathway inhibitor saridegib (IPI-926) increases lifespan in a mouse medulloblastoma model , 2012, Proceedings of the National Academy of Sciences.

[7]  Janice Branson,et al.  Epigenetic Modification of the FMR1 Gene in Fragile X Syndrome Is Associated with Differential Response to the mGluR5 Antagonist AFQ056 , 2011, Science Translational Medicine.

[8]  A. Reiss,et al.  Cholinergic dysfunction in fragile X syndrome and potential intervention: A preliminary 1H MRS study , 2009, American journal of medical genetics. Part A.

[9]  Mark F. Bear,et al.  Altered synaptic plasticity in a mouse model of fragile X mental retardation , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[10]  I. Weiler,et al.  Fragile X mental retardation protein is translated near synapses in response to neurotransmitter activation. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[11]  Lisa L. Giles,et al.  Challenges and Promises of Pediatric Psychopharmacology. , 2016, Academic pediatrics.

[12]  H. Moll,et al.  Treatment of Cognitive Deficits in Genetic Disorders: A Systematic Review of Clinical Trials of Diet and Drug Treatments. , 2015, JAMA Neurology.

[13]  D. Nguyen,et al.  A randomized double-blind, placebo-controlled trial of ganaxolone in children and adolescents with fragile X syndrome , 2017, Journal of Neurodevelopmental Disorders.

[14]  J. Crawley,et al.  Normal Performance of Fmr1 Mice on a Touchscreen Delayed Nonmatching to Position Working Memory Task123 , 2016, eNeuro.

[15]  Mark F. Bear,et al.  Correction of Fragile X Syndrome in Mice , 2007, Neuron.

[16]  P. Carlen,et al.  Reduced Cortical Synaptic Plasticity and GluR1 Expression Associated with Fragile X Mental Retardation Protein Deficiency , 2002, Molecular and Cellular Neuroscience.

[17]  G. Lynch,et al.  Physiological Activation of Synaptic Rac > PAK Signaling Is Defective in a Mouse Model of Fragile-X Syndrome , 2010 .

[18]  P. Hickmott,et al.  Genetic Removal of Matrix Metalloproteinase 9 Rescues the Symptoms of Fragile X Syndrome in a Mouse Model , 2014, The Journal of Neuroscience.

[19]  J. Naegele,et al.  Genetic manipulation of STEP reverses behavioral abnormalities in a fragile X syndrome mouse model , 2012, Genes, brain, and behavior.

[20]  R. Willemsen,et al.  Fragile X syndrome: From genetics to targeted treatment , 2017 .

[21]  L. Abbeduto,et al.  Development of an Expressive Language Sampling Procedure in Fragile X Syndrome: A Pilot Study , 2013, Journal of developmental and behavioral pediatrics : JDBP.

[22]  M. Bear,et al.  Chronic Pharmacological mGlu5 Inhibition Corrects Fragile X in Adult Mice , 2012, Neuron.

[23]  L. Saksida,et al.  The touchscreen cognitive testing method for rodents: how to get the best out of your rat. , 2008, Learning & memory.

[24]  S. Rivera,et al.  A Randomized, Double-Blind, Placebo-Controlled Trial of Low-Dose Sertraline in Young Children With Fragile X Syndrome , 2016, Journal of developmental and behavioral pediatrics : JDBP.

[25]  W. Spooren,et al.  CTEP: A Novel, Potent, Long-Acting, and Orally Bioavailable Metabotropic Glutamate Receptor 5 Inhibitor , 2011, Journal of Pharmacology and Experimental Therapeutics.

[26]  Ilse Gantois,et al.  Chronic administration of AFQ056/Mavoglurant restores social behaviour in Fmr1 knockout mice , 2013, Behavioural Brain Research.

[27]  M. Bear,et al.  Fragile X Syndrome From Genetics to Targeted Treatment , 2017 .

[28]  Randi J. Hagerman,et al.  Advances in the Treatment of Fragile X Syndrome , 2009, Pediatrics.

[29]  J. Leckman,et al.  Strengths and weaknesses in the intellectual functioning of males with fragile X syndrome. , 1987, American journal of mental deficiency.

[30]  M. Tranfaglia,et al.  Suppression of two major Fragile X Syndrome mouse model phenotypes by the mGluR5 antagonist MPEP , 2005, Neuropharmacology.

[31]  R. Gershon,et al.  The NIH Toolbox Cognitive Battery for intellectual disabilities: three preliminary studies and future directions , 2016, Journal of Neurodevelopmental Disorders.

[32]  M. Kabra,et al.  Effectiveness and Safety of Donepezil in Boys With Fragile X Syndrome , 2013, Journal of child neurology.

[33]  C. Erickson,et al.  Acamprosate in a mouse model of fragile X syndrome: modulation of spontaneous cortical activity, ERK1/2 activation, locomotor behavior, and anxiety , 2017, Journal of Neurodevelopmental Disorders.

[34]  D. Nguyen,et al.  A pilot open label, single dose trial of fenobam in adults with fragile X syndrome , 2009, Journal of Medical Genetics.

[35]  Seth M. Kelly,et al.  Increased expression of the PI3K enhancer PIKE mediates deficits in synaptic plasticity and behavior in fragile X syndrome. , 2015, Cell reports.

[36]  R. Maldonado,et al.  Possible Therapeutic Doses of Cannabinoid Type 1 Receptor Antagonist Reverses Key Alterations in Fragile X Syndrome Mouse Model , 2016, Genes.

[37]  Mika Nakamoto,et al.  Excess Phosphoinositide 3-Kinase Subunit Synthesis and Activity as a Novel Therapeutic Target in Fragile X Syndrome , 2010, The Journal of Neuroscience.

[38]  D. Nelson,et al.  The GABAA receptor is an FMRP target with therapeutic potential in fragile X syndrome , 2015, Cell cycle.

[39]  R. Hagerman,et al.  Fragile X: Leading the way for targeted treatments in autism , 2010, Neurotherapeutics.

[40]  C. Gillberg.  Attention deficit hyperactivity disorders , 1997, Acta paediatrica.

[41]  Karl Mann,et al.  Acamprosate: recent findings and future research directions. , 2008, Alcoholism, clinical and experimental research.

[42]  L. Saksida,et al.  New translational assays for preclinical modelling of cognition in schizophrenia: The touchscreen testing method for mice and rats , 2012, Neuropharmacology.

[43]  Stephen R. Morairty,et al.  Pharmacology of Basimglurant (RO4917523, RG7090), a Unique Metabotropic Glutamate Receptor 5 Negative Allosteric Modulator in Clinical Development for Depression , 2015, The Journal of Pharmacology and Experimental Therapeutics.

[44]  B. Hamel,et al.  Longitudinal changes in cognitive-behavioral levels in three children with FRAXE. , 1999, American journal of medical genetics.

[45]  L. Sandler.  Risperidone in children with autism and serious behavioral problems. , 2002, New England Journal of Medicine.

[46]  A. Fenton,et al.  Impaired cognitive discrimination and discoordination of coupled theta–gamma oscillations in Fmr1 knockout mice , 2016, Neurobiology of Disease.

[47]  C. McDougle,et al.  Cognitive effects of risperidone in children with autism and irritable behavior. , 2008, Journal of child and adolescent psychopharmacology.

[48]  G. Lynch,et al.  Physiological Activation of Synaptic Rac>PAK (p-21 Activated Kinase) Signaling Is Defective in a Mouse Model of Fragile X Syndrome , 2010, The Journal of Neuroscience.

[49]  Boris Yamrom,et al.  The contribution of de novo coding mutations to autism spectrum disorder , 2014, Nature.

[50]  I. Weiler,et al.  Open-Label Treatment Trial of Lithium to Target the Underlying Defect in Fragile X Syndrome , 2008, Journal of developmental and behavioral pediatrics : JDBP.

[51]  B. D. de Vries,et al.  Mental status of females with an FMR1 gene full mutation. , 1996, American journal of human genetics.

[52]  R. Kravitz,et al.  N-of-1 Trials in the Medical Literature: A Systematic Review , 2011, Medical care.

[53]  R. Hagerman,et al.  Review of targeted treatments in fragile X syndrome. , 2016, Intractable & rare diseases research.

[54]  Sébastien Jacquemont,et al.  Mavoglurant in fragile X syndrome: Results of two randomized, double-blind, placebo-controlled trials , 2016, Science Translational Medicine.

[55]  Sue Eckstein,et al.  Clinical investigation of medicinal products in the paediatric population , 2003 .

[56]  D. Muller,et al.  Reversal of activity‐mediated spine dynamics and learning impairment in a mouse model of Fragile X syndrome , 2014, The European journal of neuroscience.

[57]  E. Klann,et al.  Biochemical mechanisms for translational regulation in synaptic plasticity , 2004, Nature Reviews Neuroscience.

[58]  J. Montgomery,et al.  AMPA Receptors as Therapeutic Targets for Neurological Disorders. , 2016, Advances in protein chemistry and structural biology.

[59]  D. Ethell,et al.  Open-label add-on treatment trial of minocycline in fragile X syndrome , 2010, BMC neurology.

[60]  D. Hessl,et al.  Improving IQ measurement in intellectual disabilities using true deviation from population norms , 2014, Journal of Neurodevelopmental Disorders.

[61]  Ben A. Oostra,et al.  Absence of expression of the FMR-1 gene in fragile X syndrome , 1991, Cell.

[62]  S. Tonegawa,et al.  Inhibition of p21-activated kinase rescues symptoms of fragile X syndrome in mice , 2007, Proceedings of the National Academy of Sciences.

[63]  C. B. Smith,et al.  R-Baclofen Reverses a Social Behavior Deficit and Elevated Protein Synthesis in a Mouse Model of Fragile X Syndrome , 2015, The international journal of neuropsychopharmacology.

[64]  A. Arai,et al.  Pharmacology of ampakine modulators: from AMPA receptors to synapses and behavior. , 2007, Current drug targets.

[65]  Sandra Même,et al.  Rescue of fragile X syndrome phenotypes in Fmr1 KO mice by a BKCa channel opener molecule , 2014, Orphanet Journal of Rare Diseases.

[66]  S. Kushner,et al.  Ube3a reinstatement identifies distinct developmental windows in a murine Angelman syndrome model. , 2015, The Journal of clinical investigation.

[67]  A L Reiss,et al.  Specification of the neurobehavioral phenotype in males with fragile X syndrome. , 1995, Pediatrics.

[68]  M. Bear,et al.  Lovastatin Corrects Excess Protein Synthesis and Prevents Epileptogenesis in a Mouse Model of Fragile X Syndrome , 2013, Neuron.

[69]  S. Ceman,et al.  S6K1 Phosphorylates and Regulates Fragile X Mental Retardation Protein (FMRP) with the Neuronal Protein Synthesis-dependent Mammalian Target of Rapamycin (mTOR) Signaling Cascade* , 2008, Journal of Biological Chemistry.

[70]  M. Pangalos,et al.  Lessons learned from the fate of AstraZeneca's drug pipeline: a five-dimensional framework , 2014, Nature Reviews Drug Discovery.

[71]  S. Tonegawa,et al.  Rescue of fragile X syndrome phenotypes in Fmr1 KO mice by the small-molecule PAK inhibitor FRAX486 , 2013, Proceedings of the National Academy of Sciences.

[72]  M. Bear,et al.  Arbaclofen in fragile X syndrome: results of phase 3 trials , 2017, Journal of Neurodevelopmental Disorders.

[73]  R. Paylor,et al.  Genetic reduction of group 1 metabotropic glutamate receptors alters select behaviors in a mouse model for fragile X syndrome , 2011, Behavioural Brain Research.

[74]  M. Caserta,et al.  Exploring the Caregiver Burden Inventory (CBI): Further Evidence for a Multidimensional View of Burden , 1996, International journal of aging & human development.

[75]  D. Hessl,et al.  Feasibility, reliability, and clinical validity of the Test of Attentional Performance for Children (KiTAP) in Fragile X syndrome (FXS) , 2012, Journal of Neurodevelopmental Disorders.

[76]  M. Ghert,et al.  Lost in translation: animal models and clinical trials in cancer treatment. , 2014, American journal of translational research.

[77]  Stephen J. Guter,et al.  Effect of CX516, an AMPA-modulating compound, on cognition and behavior in fragile X syndrome: a controlled trial. , 2006, Journal of child and adolescent psychopharmacology.

[78]  M. Bear,et al.  Effects of STX209 (Arbaclofen) on Neurobehavioral Function in Children and Adults with Fragile X Syndrome: A Randomized, Controlled, Phase 2 Trial , 2012, Science Translational Medicine.

[79]  Jens-Uwe Peters,et al.  Fenobam: A Clinically Validated Nonbenzodiazepine Anxiolytic Is a Potent, Selective, and Noncompetitive mGlu5 Receptor Antagonist with Inverse Agonist Activity , 2005, Journal of Pharmacology and Experimental Therapeutics.

[80]  Alcino J. Silva,et al.  Reversal of learning deficits in a Tsc2+/− mouse model of tuberous sclerosis , 2008, Nature Medicine.

[81]  Angus C. Nairn,et al.  Synaptic plasticity: one STEP at a time , 2006, Trends in Neurosciences.

[82]  Ich Harmonised,et al.  INTERNATIONAL COUNCIL FOR HARMONISATION OF TECHNICAL REQUIREMENTS FOR PHARMACEUTICALS FOR HUMAN USE ICH HARMONISED GUIDELINE GENERAL CONSIDERATIONS FOR CLINICAL STUDIES E8(R1) , 2019 .

[83]  Amy L. Donaldson,et al.  Randomized, Controlled Trial of an Intervention for Toddlers With Autism: The Early Start Denver Model , 2010, Pediatrics.

[84]  A. Holmes,et al.  Predictably Irrational: Assaying Cognitive Inflexibility in Mouse Models of Schizophrenia , 2009, Frontiers in neuroscience.

[85]  Bassem A. Hassan,et al.  Expression of the GABAergic system in animal models for fragile X syndrome and fragile X associated tremor/ataxia syndrome (FXTAS) , 2009, Brain Research.

[86]  M. Gassmann,et al.  Regulation of neuronal GABAB receptor functions by subunit composition , 2012, Nature Reviews Neuroscience.

[87]  D. Chuang,et al.  Molecular actions and therapeutic potential of lithium in preclinical and clinical studies of CNS disorders. , 2010, Pharmacology & therapeutics.

[88]  S. Rivera,et al.  A Randomized Double-Blind, Placebo-Controlled Trial of Minocycline in Children and Adolescents with Fragile X Syndrome , 2013, Journal of developmental and behavioral pediatrics : JDBP.

[89]  C. B. Smith,et al.  Lithium reverses increased rates of cerebral protein synthesis in a mouse model of fragile X syndrome , 2012, Neurobiology of Disease.

[90]  A. Bruns,et al.  Chronic Metabotropic Glutamate Receptor 5 Inhibition Corrects Local Alterations of Brain Activity and Improves Cognitive Performance in Fragile X Mice , 2014, Biological Psychiatry.

[91]  Robin Christensen,et al.  Efficacy and safety of the weight-loss drug rimonabant: a meta-analysis of randomised trials , 2007, The Lancet.

[92]  Aaron Isaacs,et al.  Rescue of dendritic spine phenotype in Fmr1 KO mice with the mGluR5 antagonist AFQ056/Mavoglurant , 2012, Psychopharmacology.

[93]  Roland Heckendorn,et al.  2-Methyl-6-(phenylethynyl)-pyridine (MPEP), a potent, selective and systemically active mGlu5 receptor antagonist , 1999, Neuropharmacology.

[94]  M. Bear,et al.  Convergence of Hippocampal Pathophysiology in Syngap+/− and Fmr1−/y Mice , 2015, The Journal of Neuroscience.

[95]  E. Klann,et al.  Targeting Translation Control with p70 S6 Kinase 1 Inhibitors to Reverse Phenotypes in Fragile X Syndrome Mice , 2016, Neuropsychopharmacology.

[96]  Michael Rabbia,et al.  Effect of the mGluR5-NAM Basimglurant on Behavior in Adolescents and Adults with Fragile X Syndrome in a Randomized, Double-Blind, Placebo-Controlled Trial: FragXis Phase 2 Results , 2017, Neuropsychopharmacology.

[97]  J. Crawley,et al.  GABAB Receptor Agonist R-Baclofen Reverses Social Deficits and Reduces Repetitive Behavior in Two Mouse Models of Autism , 2015, Neuropsychopharmacology.

[98]  R. Hagerman,et al.  A controlled trial of stimulant medication in children with the fragile X syndrome. , 1988, American journal of medical genetics.

[99]  Nila A. Sathe,et al.  Medications for Adolescents and Young Adults With Autism Spectrum Disorders: A Systematic Review , 2012, Pediatrics.

[100]  W. Brown,et al.  Autism spectrum disorder in children and adolescents with fragile X syndrome: within-syndrome differences and age-related changes. , 2010, American journal on intellectual and developmental disabilities.

[101]  Michelle N. Ngo,et al.  Minocycline promotes dendritic spine maturation and improves behavioural performance in the fragile X mouse model , 2008, Journal of Medical Genetics.

[102]  J. Sweatt,et al.  Lithium ameliorates altered glycogen synthase kinase-3 and behavior in a mouse model of fragile X syndrome. , 2010, Biochemical pharmacology.

[103]  F. Gasparini,et al.  AFQ056/mavoglurant, a novel clinically effective mGluR5 antagonist: identification, SAR and pharmacological characterization. , 2014, Bioorganic & medicinal chemistry.

[104]  M. Bear,et al.  Loss of the fragile X mental retardation protein decouples metabotropic glutamate receptor dependent priming of long-term potentiation from protein synthesis. , 2010, Journal of neurophysiology.

[105]  Harry T Orr,et al.  Recovery from Polyglutamine-Induced Neurodegeneration in Conditional SCA1 Transgenic Mice , 2004, The Journal of Neuroscience.

[106]  Ich Harmonised,et al.  INTERNATIONAL CONFERENCE ON HARMONISATION OF TECHNICAL REQUIREMENTS FOR REGISTRATION OF PHARMACEUTICALS FOR HUMAN USE , 2006 .

[107]  S. Warren,et al.  FMR1 protein: conserved RNP family domains and selective RNA binding. , 1993, Science.

[108]  J. Walker,et al.  The endocannabinoid system and rimonabant: a new drug with a novel mechanism of action involving cannabinoid CB1 receptor antagonism – or inverse agonism – as potential obesity treatment and other therapeutic use , 2007, Journal of clinical pharmacy and therapeutics.

[109]  J. Henley,et al.  Synaptic AMPA receptor composition in development, plasticity and disease , 2016, Nature Reviews Neuroscience.

[110]  Therapeutic Strategies in Fragile X Syndrome: From Bench to Bedside and Back , 2015, Neurotherapeutics.

[111]  J. Turk,et al.  The use of clonidine for severe and intractable sleep problems in children with neurodevelopmental disorders , 2005, European child & adolescent psychiatry.

[112]  J. Wettstein,et al.  Metabotropic glutamate receptor 5 as drug target for Fragile X syndrome. , 2015, Current opinion in pharmacology.

[113]  L. Hartling,et al.  N-of-1 trials are a tapestry of heterogeneity. , 2016, Journal of clinical epidemiology.

[114]  Matthew W. Mosconi,et al.  Reduced habituation of auditory evoked potentials indicate cortical hyper-excitability in Fragile X Syndrome , 2016, Translational Psychiatry.

[115]  Masahiko Watanabe,et al.  Endocannabinoid-mediated control of synaptic transmission. , 2009, Physiological reviews.

[116]  A. Reiss,et al.  Genotype, molecular phenotype, and cognitive phenotype: correlations in fragile X syndrome. , 1999, American journal of medical genetics.

[117]  J. Mandel,et al.  Instability of a 550-base pair DNA segment and abnormal methylation in fragile X syndrome , 1991, Science.

[118]  R. B. Carter,et al.  Characterization of the anticonvulsant properties of Ganaxolone (CCD 1042; 3α-hydroxy-3β-methyl-5α-pregnan-20-one), a selective, high-affinity, steroid modulator of the γ-aminobutyric acid(A) receptor , 1997 .

[119]  E. Klann,et al.  Genetic Removal of p70 S6 Kinase 1 Corrects Molecular, Synaptic, and Behavioral Phenotypes in Fragile X Syndrome Mice , 2012, Neuron.

[120]  S. Chattarji,et al.  Genetic and Acute CPEB Depletion Ameliorate Fragile X Pathophysiology , 2013, Nature Medicine.

[121]  J. E. Kranz,et al.  Design, power, and interpretation of studies in the standard murine model of ALS , 2008, Amyotrophic lateral sclerosis : official publication of the World Federation of Neurology Research Group on Motor Neuron Diseases.

[122]  S. McClintock,et al.  7, 8-Dihydroxyflavone induces synapse expression of AMPA GluA1 and ameliorates cognitive and spine abnormalities in a mouse model of fragile X syndrome , 2015, Neuropharmacology.

[123]  L. Saksida,et al.  Discrimination of multidimensional visual stimuli by mice: intra- and extradimensional shifts. , 2005, Behavioral neuroscience.

[124]  C. McDougle,et al.  Aripiprazole in autism spectrum disorders and fragile X syndrome , 2010, Neurotherapeutics.

[125]  R. Gollub,et al.  Placebo Responses in Genetically Determined Intellectual Disability: A Meta-Analysis , 2015, PloS one.

[126]  F. Pammolli,et al.  The productivity crisis in pharmaceutical R&D , 2011, Nature Reviews Drug Discovery.

[127]  J. Malter,et al.  Reversal of Fragile X Phenotypes by Manipulation of AβPP/Aβ Levels in Fmr1KO Mice , 2011, PloS one.

[128]  D. Solís.  US Food and Drug Administration , 2010 .

[129]  J. Piven,et al.  Longitudinal Profiles of Adaptive Behavior in Fragile X Syndrome , 2014, Pediatrics.

[130]  Elizabeth A. McCullagh,et al.  Metformin ameliorates core deficits in a mouse model of fragile X syndrome , 2017, Nature Network Boston.

[131]  Jill L Silverman,et al.  Modeling fragile X syndrome in the Fmr1 knockout mouse. , 2014, Intractable & rare diseases research.

[132]  M. Dierssen,et al.  Targeting the endocannabinoid system in the treatment of fragile X syndrome , 2013, Nature Medicine.

[133]  M. O. James,et al.  ヘッジホッグ経路阻害剤,サリデギブ(IPI-926)はマウス髄芽腫モデルで寿命を延長する , 2012 .

[134]  B. Pennington,et al.  The Neurocognitive Phenotype of Female Carriers of Fragile X: Additional Evidence for Specificity , 1993, Journal of developmental and behavioral pediatrics : JDBP.

[135]  Y. Paulignan,et al.  A Novel Analog Reasoning Paradigm: New Insights in Intellectually Disabled Patients , 2016, PLoS ONE.

[136]  G. Dawson,et al.  Long-Term Outcomes of Early Intervention in 6-Year-Old Children With Autism Spectrum Disorder. , 2015, Journal of the American Academy of Child and Adolescent Psychiatry.

[137]  Mark F Bear,et al.  The mGluR theory of fragile X mental retardation , 2004, Trends in Neurosciences.

[138]  C. Erickson,et al.  Pharmacotherapy for Fragile X Syndrome: Progress to Date , 2016, Drugs.

[139]  R. Gollub,et al.  Certainty of genuine treatment increases drug responses among intellectually disabled patients , 2017, Neurology.

[140]  P. Lombroso,et al.  Taking STEPs forward to understand fragile X syndrome. , 2012, Results and problems in cell differentiation.

[141]  Nancy D. Giles,et al.  Cognitive, language and social-cognitive skills of individuals with fragile X syndrome with and without autism. , 2006, Journal of intellectual disability research : JIDR.

[142]  C. McDougle,et al.  Impact of acamprosate on behavior and brain-derived neurotrophic factor: an open-label study in youth with fragile X syndrome , 2013, Psychopharmacology.

[143]  A. Reiss,et al.  A solution to limitations of cognitive testing in children with intellectual disabilities: the case of fragile X syndrome , 2008, Journal of Neurodevelopmental Disorders.

[144]  L. Abbeduto,et al.  A Spoken-Language Intervention for School-Aged Boys With Fragile X Syndrome. , 2016, American Journal on Intellectual and Developmental Disabilities.

[145]  J. Epplen,et al.  Point mutation frequency in the FMR1 gene as revealed by fragile X syndrome screening. , 2014, Molecular and Cellular Probes.